What is the Tyrer‑Cuzick score, how is it interpreted, and what management recommendations correspond to low, intermediate, and high risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tyrer-Cuzick Score: Definition, Interpretation, and Risk-Based Management

The Tyrer-Cuzick (TC) model is a validated breast cancer risk assessment tool that calculates 10-year and lifetime absolute risk of developing breast cancer by incorporating detailed family history (including second-degree relatives and age at diagnosis), personal factors, breast density, and reproductive history—making it superior to simpler models when significant family history is present. 1

What the Tyrer-Cuzick Score Measures

The TC model provides:

  • 10-year absolute risk of developing breast cancer
  • Lifetime (residual) absolute risk of developing breast cancer
  • Version 8 can also estimate 5-year risk 1

The model incorporates multiple risk factors including:

  • Detailed family history (first- and second-degree relatives, age at cancer diagnosis)
  • Personal history of atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS)
  • Mammographic breast density
  • Age, reproductive history, and hormonal factors
  • Body mass index 1, 2

Risk Stratification Thresholds

High-Risk Definition

Women are considered high-risk and should be offered endocrine risk reduction therapy when they have:

  • 10-year TC risk ≥ 5% 1
  • Lifetime risk ≥ 20% (threshold for supplemental MRI screening) 3, 4

For specific age groups requiring endocrine prevention:

  • Age 40-44 years: ≥4 times the population risk
  • Age 45-69 years: ≥2 times the population risk
  • Age 60-70 years: ≥1.5 times the population risk 1

Intermediate Risk

Women with 10-year risk between 3-5% or who don't meet high-risk criteria but have elevated risk factors warrant closer surveillance and individualized discussion.

Average Risk

10-year risk <3% and lifetime risk <20% without high-risk lesions.

Management Recommendations by Risk Category

High-Risk Management (10-year risk ≥5% or lifetime risk ≥20%)

Endocrine Risk Reduction Therapy (for postmenopausal women ≥35 years):

  1. First-line options 1:

    • Anastrozole 1 mg/day orally for 5 years (preferred for most)
    • Tamoxifen 20 mg/day for 5 years (if premenopausal or contraindications to aromatase inhibitors)
    • Raloxifene 60 mg/day for 5 years (postmenopausal only)
    • Exemestane 25 mg/day for 5 years
  2. Before initiating anastrozole 1:

    • Evaluate baseline fracture risk and measure bone mineral density
    • Severe osteoporosis (T-score <-4 or >2 vertebral fractures) is a relative contraindication
    • Consider bone-protective agents (bisphosphonates, RANKL inhibitors) if moderate bone loss
    • Counsel on joint stiffness, arthralgias, vasomotor symptoms, hypertension, dry eyes, vaginal dryness
  3. Enhanced screening 3:

    • Annual screening mammography
    • Supplemental breast MRI for lifetime risk ≥20%
    • Consider contrast-enhanced mammography or molecular breast imaging if MRI contraindicated
  4. Genetic counseling referral 3, 5:

    • 66-75% of high-risk patients offered genetics consultation participate
    • 50% complete genetic testing when offered

Special Populations Requiring Endocrine Therapy Discussion

All women ≥35 years with atypical hyperplasia or LCIS should be offered endocrine therapy regardless of calculated TC score, as these lesions confer 4-10 fold increased risk (5-year risk 3-5%, 10-year risk 5-10%) 1. This applies equally to women of African descent, whose TC scores may underestimate risk.

Intermediate and Average Risk Management

Women with 10-year risk <5% and no high-risk lesions:

  • Standard screening mammography per age-appropriate guidelines
  • Periodic risk reassessment as risk increases with age 2
  • Lifestyle modification counseling

Clinical Implementation Considerations

When to Use TC vs. Other Models

Use Tyrer-Cuzick when 1, 2:

  • Significant family history present (≥2 first- or second-degree relatives with breast cancer)
  • Age at cancer diagnosis in relatives is known
  • More detailed risk assessment needed beyond simple Gail model

The TC model is more appropriate than the Gail model when family history includes age at onset or second-degree relatives 1.

Accuracy and Validation

The TC model demonstrates excellent long-term calibration:

  • Observed/Expected ratio: 0.98 (95% CI 0.94-1.02) with density included 6
  • Maintains accuracy for 10+ years of follow-up 6
  • Hazard ratio for highest risk decile vs. middle 80%: 2.55 (95% CI 2.33-2.80) when density included 6

Important Caveats

  1. Mammographic density is a major driver of TC scores: In populations with high breast density prevalence (>75%), TC may classify 13-24% more women as high-risk compared to Gail model 4

  2. TC predicts BRCA1/2 mutations better than non-BRCA pathogenic variants: Higher TC scores are associated with BRCA1/2 mutations but not reliably with CHEK2, BARD1, or other non-BRCA pathogenic variants 7. Use NCCN or ASBrS guidelines for genetic testing decisions, not TC alone.

  3. Most women identified as high-risk will never develop breast cancer: Risk models have modest discriminatory accuracy at the individual level despite good population-level calibration 2

  4. Risk assessment should begin at age 25 years per national recommendations, though implementation in routine practice remains inconsistent 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.